about
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceRandomized controlled trial of a video decision support tool for cardiopulmonary resuscitation decision making in advanced cancer.Update in Kaposi sarcoma.Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.A new prognostic score for AIDS-related lymphomas in the rituximab-era.Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaAMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNormalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomasPhase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.Spectrum of HIV lymphoma 2009.Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.Successful management of gastric perforation in stage IV diffuse large B-cell lymphoma with chemoradiation therapy, percutaneous endoscopy gastrostomy for gastric drainage, and percutaneous endoscopy jejunostomy for nutrition.Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma.Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.Successful treatment of marginal zone lymphoma with splenectomy alone despite HIV infection.Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.HIV multicentric Castleman: rituximab sans maintenance.
P50
Q28258788-62658A4F-1329-4E6A-B398-FAF28DADADA7Q30583307-05C33B85-6D50-47EB-AFD4-C487A64BE184Q33338710-0CD6A1C9-3BB4-4412-94C3-F101A844C681Q33339650-1CC7D7BA-5B86-47C6-94D9-F52C5F730C92Q33401481-47F4A7CF-3A84-4776-952A-9FFACB48A554Q33404875-8AC5B308-D629-4557-9BE0-3CD18202847CQ33407197-04767794-6D87-4CCE-BC24-EA630E7A17EBQ33806007-AD5C132D-A093-4908-B388-B895934EB2BAQ34463597-CC411E69-E257-4056-941D-E313CD22EF25Q34550216-4572E1CF-EC11-47F5-8DD7-0DD31E9AC0B7Q35511780-2129B0DA-91DD-4634-9697-855F14E1D6F2Q35836856-1557D649-66D8-4434-B518-6A5C1768972BQ36237659-5D4B3A55-BF05-4A7E-83FD-E45E4D168B8AQ36490052-CE291DBD-DEE4-480D-B219-2F3D3946E012Q36836092-3CCEED5A-74F0-4EC0-A58D-BA2D47B52BD1Q37104775-F6D9569C-8353-4CAA-956A-FA05FBFEF4E0Q37216194-FA016E25-1AAB-4A2D-8073-E5014515B8C3Q37291598-21170395-07CE-4111-8917-4374ADB16472Q37380143-7AAD9965-D029-4A59-9D7A-BB8BDD08CCF6Q37549881-35FED6B9-2CD9-47C6-8A65-BE5D118B884DQ37577385-03B81586-45BC-4AF9-9A85-5ABE9C5978C5Q37742402-BFBE6812-6F92-4D2F-8660-0433D6044888Q37854288-54D792D2-4C0D-4E19-BB6F-5975A4F0AD3CQ37858836-B2545CB5-C14A-4F55-9FE5-D1DB57A063D9Q40333043-CD6DB03E-8B0C-4823-84AE-452F68D0A478Q42174931-CE2DBD1F-DE04-4703-819C-504D09DECD37Q43550988-CF5F05B2-7672-4E41-B9F4-4F4776CAE94BQ43747236-589807AF-F36A-4CE7-8D04-D91499918786Q44088211-384C7BC4-572F-41CC-9743-83B8F959FBC5Q44252006-032B1243-1AB5-4401-97C0-E39A3F296457Q44263560-C5FA4D54-12B3-424D-AE81-FE603CF95958Q44391203-1212D013-F652-4E7F-B04D-EE23139367D9Q44482782-0C237895-21CB-41FA-9531-164761C2B61EQ44739063-25B53DCA-5394-4816-BF58-CB52C03308C3Q45227089-6E2762C2-FAA2-4EAD-8FC3-877DAA74405BQ45918039-7A1F1682-01C5-465F-A8C6-ABA875C23552Q46443812-1E3B5CF3-F76B-4C26-B288-8E57AF9930E1Q46600594-11260ADE-518E-45F7-B76C-027E346144DDQ46970940-38A20FDE-116C-413E-81EB-465AA7BAB8CCQ48276743-61658088-F4A8-4072-823B-E4AEA35E5809
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ariela Noy
@ast
Ariela Noy
@en
Ariela Noy
@es
Ariela Noy
@nl
Ariela Noy
@sl
type
label
Ariela Noy
@ast
Ariela Noy
@en
Ariela Noy
@es
Ariela Noy
@nl
Ariela Noy
@sl
prefLabel
Ariela Noy
@ast
Ariela Noy
@en
Ariela Noy
@es
Ariela Noy
@nl
Ariela Noy
@sl
P106
P21
P31
P496
0000-0002-3001-4898